Premium
Treatment of hereditary angioedema: a review (CME)
Author(s) -
Bhardwaj Neeti,
Craig Timothy J.
Publication year - 2014
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.12674
Subject(s) - icatibant , hereditary angioedema , medicine , intensive care medicine , angioedema , c1 inhibitor , dermatology , bradykinin , receptor
Hereditary angioedema ( HAE ) is a rare autosomal dominant disorder characterized by recurrent attacks of self‐limiting tissue swelling. The management of HAE has transformed dramatically with recently approved therapies in the U nited S tates. However, there is lack of awareness among physicians about these new modalities. The aim of this review is to update the practicing physician about various therapeutic options available for HAE patients. An exhaustive literature search of P ub M ed and OVID was performed to develop this article. Management of HAE is traditionally classified into treatment of acute attacks or on‐demand therapy, short‐term (preprocedural) prophylaxis, and long‐term prophylaxis. Newer therapies include C 1 esterase inhibitor ( C 1‐ INH ) and contact system modulators, namely, ecallantide and icatibant. Recombinant C 1‐ INH , which is available in E urope, is awaiting approval in the U nited S tates. C 1‐ INH concentrate is approved for prophylaxis as well as on‐demand therapy while ecallantide and icatibant are approved for acute treatment only. Effective HAE management further includes patient education, reliable access to specific medications, and regular follow‐up to monitor therapeutic response and safety.